Zdrowie i gospodarka · 13/11/2020

FDA Considers Exclusive Patent License for Field-Deployable Mass Spectrometer Diagnostic for COVID-19 and Other Viruses

The US Food and Drug Administration (FDA) is evaluating a potential exclusive patent license agreement with Advion, Inc., a biotechnology company based in Ithaca, New York, to utilize its field-deployable mass spectrometer diagnostic technology for detecting SARS, SARS-CoV-2, and other viruses, bacteria, and drug impurities.